P
Paulus Kirchhof
Researcher at University of Birmingham
Publications - 659
Citations - 119822
Paulus Kirchhof is an academic researcher from University of Birmingham. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 100, co-authored 558 publications receiving 106459 citations. Previous affiliations of Paulus Kirchhof include United States Department of Veterans Affairs & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study
Holger Reinecke,Sabine Jürgensmeyer,Christiane Engelbertz,Joachim Gerss,Paulus Kirchhof,Günter Breithardt,Rupert Bauersachs,Christoph Wanner +7 more
TL;DR: The randomised controlled phase IIIb AXADIA–AFNET 8 trial will evaluate the safety and efficacy of the factor Xa inhibitor apixaban in patients with AF requiring haemodialysis, thus exploring the efficacy of apxaban.
Journal ArticleDOI
Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study
Karl Georg Haeusler,Paulus Kirchhof,Paulus Kirchhof,Peter U. Heuschmann,Ulrich Laufs,Otto Busse,Claudia Kunze,Götz Thomalla,Darius G. Nabavi,Joachim Röther,Roland Veltkamp,Matthias Endres +11 more
TL;DR: The MonDAFIS study will be the largest study to date to evaluate whether a prolonged and systematic ECG monitoring during the initial in hospital stay has an impact on secondary stroke prevention and may have the potential to change the current guidelines recommendations regarding ECG workup after ischemic stroke.
Journal ArticleDOI
Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease
Holger Reinecke,Michael Nabauer,Andrea Gerth,Tobias Limbourg,András Treszl,Christiane Engelbertz,Lars Eckardt,Paulus Kirchhof,Karl Wegscheider,Ursula Ravens,Thomas Meinertz,Gerhard Steinbeck,Günter Breithardt +12 more
TL;DR: While CKD patients have received cardioversions, ablations, antiarrhythmic, or anticoagulation drugs significantly less often in their history, current treatments were not different if adjusted for multiple comorbidities, which might indicate an improvement in the often reported therapeutic nihilism in CKD.
Journal ArticleDOI
Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference
Renate B. Schnabel,Elena Andreassi Marinelli,Elena Arbelo,Giuseppe Boriani,Serge Boveda,Claire M. Buckley,A. John Camm,Barbara Casadei,Winnie Chua,Nikolaos Dagres,Mirko De Melis,Lien Desteghe,Søren Zöga Diederichsen,David Duncker,Lars Eckardt,Christoph Eisert,Daniel Engler,Larissa Fabritz,Ben Freedman,Ludovic Gillet,Andreas Goette,Eduard Guasch,Jesper Hastrup Svendsen,Stéphane N. Hatem,Karl Georg Haeusler,Jeff S. Healey,Hein Heidbuchel,Gerhard Hindricks,FD Richard Hobbs,Thomas Hübner,Dipak Kotecha,Michael Krekler,Christophe Leclercq,Thorsten Lewalter,Honghuang Lin,Dominik Linz,Gregory Y.H. Lip,Maja-Lisa Løchen,Wim A M Lucassen,Katarzyna Małaczyńska-Rajpold,Steffen Massberg,José L. Merino,Ralf Meyer,Lluís Mont,Michael C. Myers,Lis Neubeck,Teemu J. Niiranen,Michael Oeff,Jonas Oldgren,Tatjana S. Potpara,George Psaroudakis,Helmut Pürerfellner,Ursula Ravens,Michiel Rienstra,Lena Rivard,Daniel Scherr,Ulrich Schotten,Dipen Shah,Moritz F. Sinner,Rüdiger Smolnik,Gerhard Steinbeck,Daniel Steven,Emma Svennberg,Dierk Thomas,Mellanie True Hills,Isabelle C. Van Gelder,B. Vardar,Elena Palà,Reza Wakili,Karl Wegscheider,Mattias Wieloch,Stephan Willems,H Witt,André Ziegler,Matthias Daniel Zink,Paulus Kirchhof +75 more
TL;DR: Implementation of new evidence-based approaches to AF screening and rhythm management can improve outcomes in patients with AF and artificial intelligence (AI) can support all of the above aims, but requires advanced interdisciplinary knowledge and collaboration as well as a better medico-legal framework.
Journal ArticleDOI
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.
Craig I Coleman,Sylvia Haas,Alexander G.G. Turpie,Silvia Kuhls,Susanne Hess,Thomas Evers,Pierre Amarenco,Paulus Kirchhof,Paulus Kirchhof,A. John Camm,Xantus Investigators +10 more
TL;DR: The efficacy, safety, and ease of use of rivaroxaban may reduce anticoagulation‐treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared with vitamin K antagonists (VKAs).